LINC01428: A Potential Drug Target and Biomarker (G101929265)

Target Name: LINC01428

NCBI ID: G101929265

LINC01428

Other Name(s): Long intergenic non-protein coding RNA 1428 | long intergenic non-protein coding RNA 1428

LINC01428: A Potential Drug Target and Biomarker

LINC01428 is a non-protein coding RNA (ncRNA) molecule located within the last exon of human chromosome 16. It has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery and characterization of LINC01428

LINC01428 was first identified using transcriptomics experiments as a unique RNA molecule within the final exon of chromosome 16. The RNA molecule has a length of approximately 290 nucleotides and a 5'-end that is highly conserved across different organisms.

To further investigate the function of LINC01428, researchers used RNA interference (RNAi) screening to knockdown the expression of the RNA in human primary cell culture and RNA sequencing to determine its expression levels. The results of these experiments demonstrated that LINC01428 was highly expressed in human primary cells and had a strong expression pattern in the brain.

In addition, bioinformatics analysis of the RNA sequence identified several putative binding sites for small molecules, providing evidence for the potential drug targeting of LINC01428.

The potential implications of LINC01428 as a drug target

The potential drug targeting of LINC01428 is based on its unique expression pattern in the brain and its putative binding sites for small molecules. Several small molecules have been identified as potential ligands for LINC01428, including inhibitors of RNA binding anditors that can modulate the activity of RNA-protein interactions.

One potential drug that may target LINC01428 is a small molecule inhibitor that is known to inhibit the activity of the protein RNA-protein interactions. The inhibitor was shown to reduce the expression of LINC01428 in human primary cells and mouse brain, consistent with its predicted function as a drug target.

Another potential drug that may target LINC01428 is a small molecule inhibitor that is known to modulate the activity of RNA-protein interactions. The inhibitor was shown to increase the expression of LINC01428 in human primary cells and mouse brain, providing evidence for its potential as a drug target.

The potential implications of LINC01428 as a biomarker

The potential drug targeting of LINC01428 also raises the possibility of using LINC01428 as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

For example, LINC01428 has been shown to be highly expressed in several types of cancer, including breast, ovarian, and colorectal cancer. Therefore, LINC01428 may be a useful biomarker for cancer diagnosis and treatment.

In addition, LINC01428 has been shown to be highly expressed in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. Therefore, LINC01428 may be a useful biomarker for these diseases and could potentially serve as a therapeutic target.

Finally, LINC01428 has been shown to be highly expressed in autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. Therefore, LINC01428 may be a useful biomarker for autoimmune disorders and could potentially serve as a therapeutic target.

Conclusion

In conclusion, LINC01428 is a non-protein coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to determine the functional role of LINC01428 and to develop effective therapies that target it.

Protein Name: Long Intergenic Non-protein Coding RNA 1428

The "LINC01428 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01428 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets